Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma - Top-Institutions - MDSpire

Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma

  • By

  • Marta Canelo-Vilaseca

  • Mohamad Sabbah

  • Roberta Di Blasi

  • Caterina Cristinelli

  • Anna Sureda

  • Sophie Caillat-Zucman

  • Catherine Thieblemont

  • March 27, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Immunotherapy

  • #2

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #3

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

  • #4

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #5

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

Original Source(s)

Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma

  • by Marta Canelo-Vilaseca, Mohamad Sabbah, Roberta Di Blasi, Caterina Cristinelli, Anna Sureda, Sophie Caillat-Zucman, Catherine Thieblemont

  • March 27, 2025

Related Content

Lymphoma risk in autoimmune diseases with multiple medication use: analysis from the LIFE Study

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up